MARKET

AKBA

AKBA

Akebia Therapeut
NASDAQ
2.000
+0.140
+7.53%
Pre Market: 1.930 -0.07 -3.50% 04:09 11/07 EST
OPEN
1.850
PREV CLOSE
1.860
HIGH
2.010
LOW
1.850
VOLUME
800
TURNOVER
0
52 WEEK HIGH
2.480
52 WEEK LOW
0.8000
MARKET CAP
420.58M
P/E (TTM)
-9.8814
1D
5D
1M
3M
1Y
5Y
1D
Here's the major earnings before the open tomorrow
Seeking Alpha · 11h ago
Weekly Report: what happened at AKBA last week (1028-1101)?
Weekly Report · 2d ago
Press Release: Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dow Jones · 5d ago
Weekly Report: what happened at AKBA last week (1021-1025)?
Weekly Report · 10/28 10:34
Biotech Alert: Searches spiking for these stocks today
TipRanks · 10/25 14:45
Akebia Therapeutics: Strategic Developments and Financial Outlook Drive Buy Rating
TipRanks · 10/23 10:15
GE Aerospace, GM report quarterly earnings beats: Morning Buzz
TipRanks · 10/22 16:01
Akebia stock climbs 8% on dialysis provider supply agreement
Seeking Alpha · 10/22 14:54
More
About AKBA
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company. The Company is focused on developing and commercializing therapeutics. The Company’s portfolio and hypoxia-inducible factor (HIF)-based pipeline includes Auryxia (ferric citrate), Vafseo (vadadustat), AKB-9090 and AKB-10108. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Vafseo (vadadustat) is a HIF prolyl hydroxylase (HIF-PH), inhibitor, approved in 36 countries as a treatment for anemia due to chronic kidney disease (CKD). It utilizes third parties for the commercial distribution of Auryxia, including wholesale distributors and certain specialty pharmacy providers.

Webull offers Akebia Therapeutics Inc stock information, including NASDAQ: AKBA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AKBA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AKBA stock methods without spending real money on the virtual paper trading platform.